Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
McKinsey
Harvard Business School
Colorcon
Baxter

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Claims for Patent: 6,955,717

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,955,717
Title: Crystals and structure of Synagis Fab
Abstract:The present invention provides machine readable media embedded with the three-dimensional atomic structure coordinates of Synagis Fab, and subsets thereof, and methods of using them.
Inventor(s): Johnson; Leslie S. (Darnestown, MD), Braden; Bradford (Baltimore, MD)
Assignee: Medimmune Inc. (Gaithersburg, MD) Bowie State University (Bowie, MD)
Application Number:10/135,636
Patent Claims:1. A method of identifying a Synagis binding compound, comprising the step of using a three-dimensional structural representation of Synagis, Synagis Fab, or a fragment thereof comprising a Synagis antigen binding site, to computationally screen a candidate compound for an ability to bind the Synagis antigen binding site.

2. The method of claim 1 further including the steps of: synthesizing the candidate compound; and screening the candidate compound for Synagis binding activity.

3. A method of identifying a Synagis binding compound, comprising the steps of (a) using a three-dimensional structural representation of Synagis, Synagis Fab, or a fragment thereof comprising a Synagis antigen binding site, to computationally screen a candidate compound for an ability to bind the Synagis antigen binding site, (b) synthesizing the candidate compound; and (c) screening the candidate compound for Synagis binding activity, wherein the structural information comprises the atomic structure coordinates of residues comprising a Synagis CDR.

4. The method of claim 3 in which the Synagis CDR is L1, L2, L3, H1, H2 or H3.

5. The method of claim 4 in which the structural information comprises the antigen binding site of Synagis.

6. The method of claim 5 in which the structural information comprises the Fv fragment of Synagis.

7. The method of claim 6 in which the structural information comprises the Fab fragment of Synagis.

8. A method of identifying a Synagis binding compound comprising the step of using a three-dimensional structural representation of Synagis, Synagis Fab, or a fragment thereof comprising a Synagis antigen binding site, to computationally design a synthesizable candidate compound that binds Synagis.

9. The method of claim 8 in which the computational design comprises the steps of: identifying chemical entities or fragments capable of associating with the Synagis binding site; and assembling the chemical entities or fragments into a single molecule to provide the structure of the candidate compound.

10. The method of claim 9 further including the steps of: synthesizing the candidate compound; and screening the candidate compound for Synagis binding activity.

11. A method of identifying a Synagis binding compound comprising the step of using a three-dimensional structural representation of Synagis, Synagis Fab, or a fragment thereof comprising a Synagis antigen binding site, to computationally design a synthesizable candidate compound that binds Synagis, wherein the structural information comprises the atomic structure coordinates of residues comprising a Synagis CDR.

12. The method of claim 11 in which the Synagis CDR is L1, L2, L3, H1, H2 or H3.

13. The method of claim 11 in which the structural information comprises the antigen binding site of Synagis.

14. The method of claim 11 in which the structural information comprises the Fv fragment of Synagis.

15. The method of claim 12 in which the structural information comprises the Fab fragment of Synagis.

16. The method of claim 11 in which the computational design comprises the steps of: identifying chemical entities or fragments capable of associating with the Synagis binding site; and assembling the chemical entities or fragments into a single molecule to provide the structure of the candidate compound.

17. The method of claim 16 further including the steps of: synthesizing the candidate compound; and screening the candidate compound for Synagis binding activity.

Details for Patent 6,955,717

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Medimmune SYNAGIS palivizumab VIAL 103770 001 1998-06-19   Start Trial Medimmune Inc. (Gaithersburg, MD) Bowie State University (Bowie, MD) 2021-05-01 RX search
Medimmune SYNAGIS palivizumab VIAL 103770 002 1998-06-19   Start Trial Medimmune Inc. (Gaithersburg, MD) Bowie State University (Bowie, MD) 2021-05-01 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Express Scripts
Merck
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.